Dermatomyositis Pipeline Review: H1 2018 - Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

DUBLIN--()--The "Dermatomyositis - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 9, 6, 5, 13, 8 and 2 respectively.

Companies Mentioned

  • AbbVie Inc
  • Adello Biologics LLC
  • Alteogen Inc
  • Amgen Inc
  • Biocad
  • Biocon Ltd
  • Bionovis SA
  • Celgene Corp
  • Coherus BioSciences Inc
  • Eli Lilly and Co
  • Fresenius SE & Co KGaA
  • Galapagos NV
  • Genor BioPharma Co Ltd
  • Immunwork Inc
  • Innovent Biologics Inc
  • Izana Bioscience Ltd
  • Mycenax Biotech Inc
  • Nichi-Iko Pharmaceutical Co Ltd
  • Novartis AG
  • Nuevolution AB
  • Oncobiologics Inc
  • Pfizer Inc
  • Protalix BioTherapeutics Inc
  • Reliance Life Sciences Pvt Ltd
  • Sandoz International GmbH
  • Shanghai Pharmaceutical Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • UCB SA
  • Xbrane Biopharma AB

Key Topics Covered

  1. Introduction
  2. Ankylosing Spondylitis (Bekhterev's Disease) - Overview
  3. Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Development
  4. Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment
  5. Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development
  6. Ankylosing Spondylitis (Bekhterev's Disease) - Drug Profiles
  7. Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects
  8. Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products
  9. Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones
  10. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/8hhwp4/dermatomyositis?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Musculoskeletal Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Musculoskeletal Disorders Drugs